# Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands.

**Tumor:** Cáncer de esófago
**Autores:** van Laarhoven H
**Revista:** EClinicalMedicine (2025)
**PMID:** 39911244 | **PMCID:** PMC11795631
**DOI:** [10.1016/j.eclinm.2024.103067](https://doi.org/10.1016/j.eclinm.2024.103067)
**Fuente:** PubMed Central (open access)

## Relevancia
Cáncer de esófago/UGE tras quimiorradioterapia CROSS o quimioterapia FLOT: aborda pCR ganglionar, supervivencia según yp-stage y patrones de diseminación nodal. Análogo a mama: el ypN0 es el factor pronóstico independiente más robusto tras tratamiento neoadyuvante.

## Abstract
Recent studies in patients with resectable adenocarcinoma of the esophagus or gastroesophageal junction (GEJ)-Neo-AEGIS and ESOPEC-have explored the comparison of neoadjuvant chemoradiotherapy (nCRT) with chemotherapy, with conflicting results. From the Netherlands Cancer Registry, patients were selected with resectable esophageal/GEJ adenocarcinoma treated with nCRT according to CROSS. Of 4765 included patients, 4170 (87.5%) completed the full CROSS regimen. A pCR was observed in 704 (20.5%) of 3439 patients who underwent surgical resection within 16 weeks. The median overall survival (OS) was 33.7 months with a 3-year OS rate of 48.1%. These real-world results underscore the potential of the CROSS regimen in daily clinical practice.

## Acceso
Disponible en PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11795631/

---
*Datos de PubMed. Citar: doi 10.1016/j.eclinm.2024.103067*
